Head and Neck Squamous Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Head and Neck Squamous Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-07-31Clinical Trial Update: Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer [Phase 3]
The Phase III trial comparing PET/CT surveillance with CTSurveillance for head and neck squamous cell carcinoma was terminated.
-
CLINICAL_TRIALS trial_result · 2017-07-28Clinical Trial Update: DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole [Phase 1, Phase 2]
Phase I/II trial (DAHANCA 28A) investigates accelerated, hyperfractionated radiotherapy with concomitant cisplatin and nimorazole in head an…
-
CLINICAL_TRIALS trial_result · 2017-07-27Clinical Trial Update: Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA) [Phase 2]
Phase 2 clinical trial update evaluating the combination of RADPLAT (radiation with intra-arterial cisplatin) and Tarceva (erlotinib) for lo…
-
CLINICAL_TRIALS trial_result · 2017-07-06Clinical Trial Update: Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) [Phase 2]
Phase 2 trial of pembrolizumab (MK-3475) in recurrent or metastatic head and neck squamous cell carcinoma after platinum and cetuximab thera…
-
CLINICAL_TRIALS trial_result · 2017-07-06Clinical Trial Update: A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) [Phase 1]
This completed Phase 1 trial evaluated MEHD7945A in combination with cisplatin/5-FU or paclitaxel/carboplatin in patients with recurrent/met…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-06-26Clinical Trial Update: Oral Rigosertib for Squamous Cell Carcinoma [Phase 2]
A Phase 2 clinical trial evaluating oral rigosertib for various squamous cell carcinomas has completed.
-
CLINICAL_TRIALS trial_result · 2017-06-23Clinical Trial Update: Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer [Phase 1]
Phase 1 trial evaluating platinum-based chemoradiotherapy with rigosertib for head and neck cancer has completed.
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma [Phase 2]
Phase 2 trial investigating DCA in combination with cisplatin and definitive radiation for head and neck squamous cell carcinoma; study comp…
-
CLINICAL_TRIALS trial_result · 2017-06-09Clinical Trial Update: A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This post-marketing surveillance trial evaluating cetuximab plus radiotherapy in unresectable locally advanced head and neck squamous cell c…
-
CLINICAL_TRIALS trial_result · 2017-05-18Clinical Trial Update: Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy [Phase 2]
Phase 2 trial evaluating a three-drug antiemetic regimen (fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone) for prev…
-
CLINICAL_TRIALS trial_result · 2017-05-11Clinical Trial Update: Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma [Phase 2]
A Phase 2 trial evaluating cetuximab plus docetaxel with low-dose fractionated radiation for head and neck squamous cell carcinoma was termi…
-
CLINICAL_TRIALS trial_result · 2017-04-14Clinical Trial Update: Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer [Phase 2]
A Phase 2 trial evaluating the combination of capecitabine and vorinostat for recurrent/metastatic head and neck squamous cell carcinomas wa…
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]
Phase 2 study evaluating chemotherapy with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma; results…
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer [Phase 2]
Phase 2 trial results are reported for a chemoradiation regimen including cetuximab and pemetrexed with or without bevacizumab in locally ad…
-
CLINICAL_TRIALS trial_result · 2017-03-06Clinical Trial Update: Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy [Phase 2]
Phase 2 trial of lapatinib with radiation for stage III-IV head and neck squamous cell carcinoma in patients unable to tolerate concurrent c…
-
CLINICAL_TRIALS trial_result · 2017-03-06Clinical Trial Update: SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]
Phase 2 clinical trial update for SB-715992 in patients with recurrent or metastatic head and neck cancer; the study completed and results w…
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: Quantitative Optical Sensor Findings in Head & Neck Squamous Cell Carcinoma
Clinical trial update reporting quantitative optical sensor findings in head and neck squamous cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma [Phase 1]
Phase 1 trial evaluating radiation plus cetuximab and an EGFR antisense DNA agent for head and neck squamous cell carcinoma; the study was t…
-
CLINICAL_TRIALS trial_result · 2017-02-08Clinical Trial Update: Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis [EARLY_Phase 1]
A pilot early-phase study of metformin in head and neck squamous cell carcinoma has been terminated. The study investigated metformin effect…
-
CLINICAL_TRIALS trial_result · 2017-02-06Clinical Trial Update: Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy [Phase 2]
Phase 2 trial evaluating temsirolimus with or without cetuximab in patients with recurrent and/or metastatic head and neck squamous cell car…
-
CLINICAL_TRIALS trial_result · 2017-01-19Clinical Trial Update: Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck [Phase 1]
A Phase 1 study evaluating chemotherapy plus radiation therapy for patients with head and neck squamous cell carcinoma has been completed.
-
CLINICAL_TRIALS trial_result · 2017-01-13Clinical Trial Update: Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT [Phase 3]
A Phase 3 trial comparing prophylactic topical dapsone 5% gel with moisturizer to prevent cetuximab-induced acneiform rash in patients with …
-
CLINICAL_TRIALS trial_result · 2017-01-04Clinical Trial Update: Randomized Amifostine For SCCHN [Phase 2]
Phase 2 randomized trial of amifostine (Ethyol) to mitigate chemotherapy- and radiotherapy-related toxicities (mucositis, xerostomia) in hea…
-
CLINICAL_TRIALS trial_result · 2016-11-29Clinical Trial Update: DAHANCA 25B: Progressive Resistance Training as Intervention for Regaining Muscle Mass After Radiation Therapy in Patients With HNSCC [NA]
This completed trial evaluated progressive resistance training as an intervention to regain muscle mass after radiation therapy in patients …
-
CLINICAL_TRIALS trial_result · 2016-11-25Clinical Trial Update: DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC [Phase 3]
Phase 3 trial DAHANCA 19 evaluates the EGFR inhibitor zalutumumab for outcomes after curative radiotherapy in head and neck cancer. The docu…